Pituitary dysfunction and association with fatigue in stroke and other acute brain injury

H A Booij¹, W D C Gaykema², K A J Kuijpers², M J M Pouwels³ and H M den Hertog¹

¹Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands
²Roessingh Rehabilitation Center, Enschede, the Netherlands
³Department of Endocrinology, Medisch Spectrum Twente, Enschede, the Netherlands

Correspondence should be addressed to H A Booij: h.a.booij@gmail.com

Abstract

Background: Poststroke fatigue (PSF) is a highly prevalent and debilitating condition. However, the etiology remains incompletely understood. Literature suggests the co-prevalence of pituitary dysfunction (PD) with stroke, and the question raises whether this could be a contributing factor to the development of PSF. This study reviews the prevalence of PD after stroke and other acquired brain injuries and its association with fatigue.

Summary: We performed a bibliographic literature search of MEDLINE and EMBASE databases for English language studies on PD in adult patients with stroke, traumatic brain injury (TBI) or aneurysmatic subarachnoid hemorrhage (aSAH). Forty-two articles were selected for review. Up to 82% of patients were found to have any degree of PD after stroke. Growth hormone deficiency was most commonly found. In aSAH and TBI, prevalences up to 49.3% were reported. However, data differed widely between studies, mostly due to methodological differences including the diagnostic methods used to define PD and the focus on the acute or chronic phase. Data on PD and outcome after stroke, aSAH and TBI, prevalences up to 49.3% were reported. However, data differed widely between studies, mostly due to methodological differences including the diagnostic methods used to define PD and the focus on the acute or chronic phase. Data on PD and outcome after stroke, aSAH and TBI, were conflicting. No studies were found investigating the association between PD and PSF. Data on the association between PD and fatigue after aSAH and TBI were scarce and conflicting, and fatigue is rarely been investigated as a primary end point.

Key messages: Data according to the prevalence of PD after stroke and other acquired brain injury suggest a high prevalence of PD after these conditions. However, the clinical relevance and especially the association with fatigue need to be established.

Introduction

Stroke is one of the most common causes of morbidity and case fatality in developing countries. Although mortality has declined with improved acute phase treatment, costs of care due to long-term disability are high. Functional outcome is influenced not only by factors related to acute stages of stroke, but also by factors emerging during recovery, including fatigue. Fatigue is a highly prevalent and debilitating condition, which often persists after stroke and has been recognized as an important predictor of death, disability and worse quality of life (1, 2, 3).

The clinical entity of poststroke fatigue (PSF) is still poorly understood and evidence based treatment is scarce. Recent literature suggests the co-prevalence of pituitary dysfunction (PD) with stroke. As the symptomatology of poststroke symptoms such as fatigue and cognitive disturbances overlap with that of PD, the question raises whether there could be a causal relationship. If poststroke PD plays a role in the pathogenesis of PSF, it might be a target for treatment of PSF. In this review, we aim to give an overview of the literature on the prevalence and...
possible predictors of PD in stroke and the association with fatigue. We also searched for articles on PD after aneurysmatic subarachnoid hemorrhage (aSAH) and traumatic brain injury (TBI) and the association with fatigue, since the mechanism of PD in these other acute acquired brain injuries might be similar as in stroke. A better understanding of the etiology and effect of PD in these acute acquired brain injuries may assist in developing rational interventions and improve outcome.

Methodology

MEDLINE and EMBASE were searched for potentially relevant articles for the period January 1995 until April 2017. The search strategy included a combination of the key words ‘pituitary dysfunction’, ‘pituitary diseases’, ‘hypopituitaritis’, ‘stroke’, ‘cerebral infarction’, ‘cerebral hemorrhage’, ‘subarachnoid hemorrhage’, ‘traumatic brain injury’, ‘brain injury’, ‘acquired brain injury’ and ‘fatigue’ and their entry terms, using Medical Subject Headings (MeSH) terms where appropriate. Peer-reviewed, English language studies that investigated PD in adult patients with stroke, TBI or subarachnoid hemorrhage were included. Publications with titles and abstracts suspected to meet the eligibility criteria for this review were selected for detailed analysis. Additional publications meeting the inclusion criteria were selected from the reference list of those articles included in this review. Two authors (Booij and Gaykema) independently assessed study eligibility. Any discrepancies were resolved through a consensus discussion. A total of 5412 studies were identified of which 42 met our inclusion criteria.

PD in acute acquired brain injury

Pathophysiology

The pituitary gland receives its blood supply mainly from the long hypophyseal portal vessels, which travel from the internal carotid arteries and anterior circle of Willis alongside the infundibulum to the pituitary gland. Less than 30% is vascularized by the short hypophyseal portal vessels, which arise from branches of the intracavernous internal carotid artery. The long portal vessels and the pituitary stalk are particularly vulnerable to injury due to mechanical forces. This mechanism has first been shown by Daniel et al. in 1959, who presented five cases of traumatic infarction of the anterior pituitary gland in TBI considered due to transection of the pituitary stalk at the time of injury (4). This, and other secondary mechanisms after TBI, such as hypotension, hypoxia and raised intracranial pressure might be responsible for the development of PD (5). The same concept might be applied in part to brain injury due to stroke as well.

PD and stroke

Literature on the prevalence of PD in stroke is scarce, especially for the subacute and chronic phase. The most commonly found endocrine disturbance is growth hormone deficiency (GHD) (Table 1). This is in line with the fact that growth hormone (GH) is produced in the lateral wings of the adenohypophysis, which seems to be more vulnerable to damage. In a prospective cohort study with 42 ischemic stroke patients, GHD was found in 11.9%, central hypogonadism in 7.1% and central adrenal insufficiency in 2.4% (6). Occurrence of PD was not related to the clinical severity of the acute event and did not influence the outcome after stroke. However, higher insulin-like growth factor-1 (IGF-1) levels were observed in patients with better outcome, suggesting a possible neuroprotective role for IGF-1 after ischemic stroke. In a later study with two consecutive measurements, a prevalence of PD of 35.7% was found at 1–3 months after stroke and 37.5% at 12–15 months after stroke (7). GHD and central hypogonadism were the most frequent PDs. In 8.3% of patients, PD improved, and in 6.2%, it worsened over time. Predictors of PD were diabetes mellitus and more severe stroke (clinically and radiologically). PD was associated with an unfavorable functional outcome (modified Ranking Scale score 3–5 at 1–3 months (2.75 ± 0.20 vs 2.02 ± 0.19; P = 0.031) and at 12–15 months (2.67 ± 0.24 vs 1.53 ± 0.30; P = 0.002)). Again, there was an association between higher IGF-1 levels and favorable outcome. Another prospective cohort study in ischemic stroke patients showed a staggering prevalence of 82% having some degree of PD assessed at 66–274 days after the event, again with impaired GH response being the most commonly found (79.5%) (8). Only patients with ischemia of the middle cerebral artery or thalamus region were included. No association between PD and stroke outcome was detected.

Prevalence of PD in other acute acquired brain injury

PD was thought to be a rare consequence of TBI. However, in 2000, a review was published including 367 cases of posttraumatic PD, consisting of case reports or series

http://www.endocrineconnections.org
https://doi.org/10.1530EC-18-0147 © 2018 The authors Published by Bioscientifica Ltd

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives4.0International License.

Downloaded from Bioscientifica.com at 12/12/2018 11:37:35AM via free access
between 1970 and 1998 (9). This review marks the start of systematic research concerning this topic. In a large cross-sectional study in 102 TBI patients, a prevalence of GHD was found in 10.7%, 11.8% had hypogonadism and 12.7% were defined as adrenocorticotropic hormone (ACTH) deficient (10). In a systematic review of 13 studies including 911 patients, the pooled prevalence of PD in the chronic phase after TBI and aSAH were 27.5% and 47%, respectively (11). Again, GHD was most commonly found. In another comprehensive systematic review, 16 studies (1203 patients) on the prevalence of PD in the chronic phase after TBI were identified (12). A prevalence of 27.8% of any degree of PD was found, based on basal screening tests. However, when only studies were included that used confirmatory testing, this number dropped to 14.7%. In a systematic review of 20 studies in aSAH patients, a prevalence of PD of 49.3% was found within the first 6 months after injury (13). This percentage decreased to 25.6% in the chronic phase. Deficiencies in somatotropic axis, adrenocorticotropic axis and gonadotropic axis were most frequent. Younger patients were more likely to have PD in the acute phase. No association between PD and functional outcome was found. Since there was a wide heterogeneity among the studies according to the detected prevalence rate of PD ($I^2 = 62.8–93.5$), interpretation should be done with caution. One of the first prospective studies, in which 23 TBI patients were screened for PD during the acute phase and at 24–36 months post injury, showed important dynamic hormonal changes over time (14). The thyrotropic and gonadotropic system recovered completely within the follow-up period. However, new-onset corticotropic (26%) and somatotropic (4.3%) deficiency were demonstrated. This is in line with a meta-analysis of 17 studies (in part the same studies as in aforementioned systematic review), in which pooled prevalence of PD was 31% in studies performed between 3 and 6 months after aSAH (15). In long-term studies (>6 months), PD prevalence was found to be 25%. These results suggest an improvement in PD over time, however, new-onset hormone deficiencies developed in some patients during the follow-up period. As in the aforementioned review, an important limitation of this meta-analysis is a high variation in prevalence of PD across the studies, which is partly due to differences in the diagnostic tests and cutoff values being used. In a multicenter database study, long-term anterior pituitary insufficiency was investigated by analyzing 351 patients at least 1 year after TBI and aSAH, mostly recruited from endocrinological departments (16). Patients tested 1–2 years after the event had most commonly neuroendocrinological disturbances (defined as lowered basal hormone levels) in the gonadotropic axis (19%), followed by the somatotropic axis (11.5%). Patients tested at more than 5 years after the event, however, had a different pattern: somatotropic insufficiency (24.1%) was followed by gonadotropic insufficiency (16.3%). There was no significant difference in the prevalence of PD between TBI and aSAH. As recruitment took place in endocrinological wards, and only patients in medical treatment were included, absolute prevalence rates might be overestimated when compared to the general SAH population. However, the results suggest that patients suffering from aSAH or TBI are still at risk for PD even years after the event. The association of PD in TBI is mostly

### Table 1 Prevalence and predictors of pituitary dysfunction after stroke.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%)</th>
<th>Predictors of PD (Odds (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bondanelli, 2006 (6)</td>
<td>Prospective cohort</td>
<td>42</td>
<td>Mean NIHSS 11.02 ± 0.87</td>
<td>19–209 days, mean 62 ± 8</td>
<td>Any degree 19, GH 11.9, LH/FSH 7.1, ACTH 2.4, TSH 0</td>
<td>Not assessed</td>
</tr>
<tr>
<td>Bondanelli, 2010 (7)</td>
<td>Prospective cohort</td>
<td>56</td>
<td>Mean NIHSS 10.75 ± 0.55</td>
<td>1–3 months and 12–15 months</td>
<td>1–3 months: any degree 35.7, GH 30.3, LH/FSH 10.7, ACTH 1.8, TSH 0</td>
<td>Diabetes mellitus: 1–3 months: 5.0 (1.5–17.2) 12–15 months: 8.1 (1.9–33.1)</td>
</tr>
<tr>
<td>Boehnkce, 2011 (8)</td>
<td>Prospective cohort</td>
<td>46</td>
<td>Median NIHSS 6, range 1–15</td>
<td>66–274 days, mean 128 ± 46</td>
<td>Any degree GHD 78.5, LH/FSH 4.3, ACTH 14.6, TSH 0</td>
<td>Initial NIHSS ≥15: 1–3 months: 5.7 (1.0–32.6) 12–15 months: 11.2 (1.2–105.2)</td>
</tr>
</tbody>
</table>

ACTH, adrenocorticotropic hormone; ASPECTS: Alberta stroke program early CT score (A normal CT scan has an ASPECTS value of 10. A score of zero indicates diffuse ischemia); FSH, follicle-stimulating hormone; GH, growth hormone; LH, luteinizing hormone; NIHSS, National Institutes of Health Stroke Scale; PD, pituitary dysfunction; TSH, thyroid-stimulating hormone.
studied in traffic-related injuries. Recently, the association of PD and sports-related injuries including chronic repetitive head trauma is getting more attention and PD, in particular isolated GH deficiency, is not uncommon in boxers, kickboxers and football players (17, 18). Table 2 summarizes design, patient selection and characteristics and prevalence of PD of the various studies.

**PD and functional outcome in other acute acquired brain injury**

Literature on the association between PD and functional outcome is conflicting (Table 3). Post-TBI PD has been associated with a lower health-related quality of life (19), unfavorable lipid and body composition profile (19, 20) and increased disability and symptoms of depression (21), measured between 1 and 5 years post injury. In a consecutive cohort of 78 men with TBI, a prevalence of posttraumatic hypogonadotropic hypogonadism was found in 44% of patients during the first year post injury (22). Hypogonadotropic hypogonadism was associated with worse global outcome scores, more disability and reduced functional cognition at 6 and 12 months post TBI. A prospective cohort study with 51 aSAH patients reported an association between PD and poor outcome, as defined by a lower Glasgow Outcome Scale Score (23). Previous studies, however, did not find an association between PD and outcome after aSAH (24, 25, 26). A cross-sectional study of 34 patients with TBI or aSAH 5–12 months after the event found a relation between PD and diminished functional performance. However, this association was not adjusted for severity of TBI or aSAH (27). The main limitation of most of these studies is the small number of subjects and study design. More prospective studies with larger numbers of subjects are important to further investigate the effect of PD on outcome.

**Predictors of PD in other acute acquired brain injury**

Studies on recommendations on selecting patients with acute acquired brain injury for screening of PD are limited. A cross-sectional Japanese study evaluating PD between 3 and 36 months after aSAH showed the prevalence of GHD to be 8.5% (28). All patients with GHD (n=5) had aneurysm location in the anterior cerebral artery and the internal carotid artery. The authors concluded that aneurysm location in these regions is a possible risk factor for GHD and recommend screening for PD in these patient categories. However, patient numbers were small with aneurysm location in anterior cerebral artery and internal carotid artery being overrepresented in the total study group, doubting the relevance of this finding. In a systematic review of 27 studies, increased age, TBI severity and skull fractures predicted anterior pituitary disorders in post-TBI patients (29). However, the authors only found a limited number of studies with a low risk of bias. Other possible predictors of PD after TBI are increased intracranial pressure (30) and diffuse axonal injury (31). In a prospective cohort study on PD in aSAH patients, hydrocephalus was an independent predictor of PD after 6 months (32). One study on PD after TBI compared 112 patients referred for pituitary evaluation on the basis of suggestive symptoms with a control group of 137 post-TBI patients (33). Patients referred with menstrual dysfunction had more GH, ACTH, gonadotropin deficiency and any pituitary hormone deficit than the systematically screened patients. Men with symptoms of hypogonadism (loss of libido, erectile dysfunction) had more GH, gonadotropin and thyroid-stimulating hormone deficiency than the systematically screened patients. However, patients with nonspecific symptoms such as fatigue, anergia and weight loss were no more likely to have PD than those consecutively screened. The authors conclude that menstrual dysfunction and symptoms of hypogonadism are an accurate indication for screening for PD in post-TBI patients. However, in the absence of these clearly defined symptoms, no recommendations can be made on screening behavior. Table 4 summarizes design, patient selection and characteristics and prevalence and predictors of PD of the various studies.

**Effect of hormonal suppletion on outcome in other acute acquired brain injury**

Only a few studies evaluated the effect of hormonal substitution in PD after acquired brain injury. In a randomized double-blind controlled trial, 23 patients with post-TBI GHD or GH insufficiency were randomized for either recombinant human GH or placebo for 1 year (34). Outcome measures were neuropsychological and functional abilities. Improvement in the treatment group was seen in four measurements taken: finger tapping (Time×Group, P=0.01), the WAIS-III processing speed index (Time×GH Level×Group, P=0.03), the Wisconsin Card Sorting Test (Time×GH Level×Group, P=0.01) and the California Verbal Learning Test-II (Main effect for time in treatment group only, P=0.03). The authors concluded that some of the cognitive deficiencies seen in TBI could be improved by GH suppletion. However, since in the other 39 measurements no difference was measured between the

---

http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0147
© 2018 The authors
Published by Bioscientifica Ltd
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
two groups, this raises the question whether these findings are meaningful or just a coincidence. Another study in patients with cognitive disorders after TBI compared the effect of subcutaneous GH administration of 1 mg/day in 11 patients with GHD with placebo in 8 patients without GHD (35). Treatment duration was 3 months. Mean time since injury was 44.6 months (study group, s.d. 35.6) and 46.6 months (control group, s.d. 28.8). Main outcome measure was the neuropsychological test WAIS before and after treatment. GHD patients reached significantly greater improvements than controls in similarities ($P<0.01$), in vocabulary, verbal IQ and total IQ ($P<0.05$). At the end of the treatment period, plasma IGF-I levels were similar in both groups. The authors concluded that the exogenous GH administration is likely to be responsible for the significant differences found. In an observational

![Image](https://www.endocrineconnections.org)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Table 2  Prevalence of pituitary dysfunction in traumatic brain injury and aneurysmatic subarachnoid hemorrhage.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%) (95% CI if published)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agha, 2004 (10)</td>
<td>Cross-sectional</td>
<td>102, TBI</td>
<td>100% GCS ≤13, 58% GCS ≤8 Median GCS 8</td>
<td>6–36 months, median 17</td>
<td>Any degree 28.4 (19.7–37.2), GH 10.7 (4.8–16.8), LH/FSH 11.8 (5.5–18.0), ACTH 12.7 (6.3–19.2), TSH 1 (0–2.9)</td>
</tr>
<tr>
<td>Schneider, 2007 (11)</td>
<td>Systematic review, 13 studies between 2000 and 2007</td>
<td>911, 809 TBI, 102 aSAH</td>
<td>NR</td>
<td>At least 5 months</td>
<td>Any degree 29.8 (25.3–31.1) (TBI 27.5 (22.8–28.9) and aSAH 47 (37.4–56.8)), GH 3.8 (11.7–16.2), LH/FSH 11.7 (9.7–13.8), ACTH 9.6 (7.8–11.6), TSH 4.3 (3.2–5.8)</td>
</tr>
<tr>
<td>Tanriverdi, 2015 (12)</td>
<td>Systematic review, 16 studies between 2004 and 2011</td>
<td>1203, TBI</td>
<td>Heterogeneous data</td>
<td>At least 3 months</td>
<td>Abnormal screening test ($N=1203$): any degree 27.8, GH 13.0, LH/FSH 10.2; ACTH 11.8, TSH 4.2</td>
</tr>
<tr>
<td>Robba, 2016 (13)</td>
<td>Systematic review and meta-analysis, 20 studies between 2005 and 2015</td>
<td>Acute phase: 510, aSAH Chronic phase: 1114, aSAH</td>
<td>NR</td>
<td>Acute phase: &lt;6 months, chronic phase: &gt;6 months</td>
<td>Acute phase: any degree 49.3 (41.6–56.9)</td>
</tr>
<tr>
<td>Kleindienst, 2009 (14)</td>
<td>Prospective cohort</td>
<td>71, TBI; follow-up 23</td>
<td>33.8% GCS 12-15, 45.1% GCS 9-11, 21.1% GCS 3-8</td>
<td>Acute phase: 0, 3 and 7 days Chronic phase: 24–36 months</td>
<td>Acute phase: any degree NR, GH 25–36, LH/FSH 13–24, ACTH 18–25, TSH 8–24</td>
</tr>
<tr>
<td>Krewer, 2016 (16)</td>
<td>Cross-sectional</td>
<td>351, TBI and aSAH</td>
<td>TBI: 20.8% GCS 13–15, 2.4% GCS 9–12, 15.1% GCS 3–8, 61.6% missing aSAH: 46.2% H&amp;H 1-2, 31.1% H&amp;H 3-4, 7.5% H&amp;H 5, 13.2% missing</td>
<td>1–55 years</td>
<td>Depending on criteria used: lowered basal hormonal values, physician’s diagnosis or stimulation test: GH 13.3–20, LH/FSH 11.1–14.4, ACTH 7.3–25.3, TSH 3.3–7.2</td>
</tr>
</tbody>
</table>

ACTH, adrenocorticotropic hormone; aSAH, aneurysmatic subarachnoid hemorrhage; FSH, follicle-stimulating hormone; GCS, Glasgow Coma Scale score (severe: 3–8; moderate: 9–12; mild: 13–15); GH, growth hormone; H&H, Hunt and Hess score (clinical severity ranging from 0 (minimal or no symptoms) to 5 (deep coma)); LH, luteinizing hormone; NR, not reported; PD, pituitary dysfunction; TBI, traumatic brain injury; TSH, thyroid-stimulating hormone.
### Table 3  Prevalence of pituitary dysfunction and association with functional outcome in traumatic brain injury and aneurysmatic subarachnoid hemorrhage.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%)</th>
<th>Association of PD with functional outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Klose, 2007 (18)</td>
<td>Cross-sectional</td>
<td>104, TBI</td>
<td>42.3% GCS 13–15, 19.2% GCS 9–12, 38.5% GCS ≤8</td>
<td>10–27 months</td>
<td>Any degree 15.4, GH 15, LH/FSH 2; ACTH 5; TSH 2</td>
<td>PD patients: Higher 12-month LDL cholesterol, waist circumference and total fat mass (all ( P &lt; 0.05 )) Higher increase in total cholesterol during follow-up (( P = 0.01 )) Worse quality of life EuroQol-5D visual analog scale, ( P = 0.03 ) Quality of Life Assessment of GHD in adults, ( P = 0.01 )</td>
</tr>
<tr>
<td>Giuliani, 2016 (19)</td>
<td>Cross-sectional</td>
<td>48, TBI</td>
<td>Complicated mild TBI (GCS 13–15)</td>
<td>1 and 5 years</td>
<td>1 year: any degree NR, GH 34, LH/FSH 0, ACTH 0, TSH 4.3 5 year: any degree NR, GH 48, LH/FSH 0, ACTH 0, TSH 4</td>
<td>GHD patients: higher BMI, waist circumference, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and visceral adipose index (all ( P &lt; 0.02 ))</td>
</tr>
<tr>
<td>Kreber, 2016 (20)</td>
<td>Cross-sectional</td>
<td>235, TBI</td>
<td>80% moderate in disability scale</td>
<td>Mean 367 days, SEM 46.9</td>
<td>GH 77</td>
<td>GHD patients: Higher disability (DRS, ( F(1, 205) = 6.280, P = 0.013 )) Less independence at admission (ILS, ( F(1, 200) = 4.247, P = 0.041 )) More depressive symptoms (BDI-II, ( F(2, 101) = 4.15, P = 0.019 ))</td>
</tr>
<tr>
<td>Barton, 2016 (21)</td>
<td>Prospective cohort</td>
<td>78, male TBI</td>
<td>100% GCS ≤8</td>
<td>Repeated measurements from week 1 until 1 year</td>
<td>LH 44</td>
<td>PHH patients: Lower total and cognitive functional independence score at 6 (( P = 0.011 ) and ( P = 0.007 )) and 12 months (( P = 0.002 ) and ( P = 0.001 )) Higher score on DRS and more lack of energy at 12 months (( P = 0.010 ) and ( P = 0.028 )) &gt;3-fold increased risk of having an unfavorable GOS outcome at 6 and 12 months (( P &lt; 0.05 ))</td>
</tr>
<tr>
<td>Kronvall, 2014 (22)</td>
<td>Prospective cohort</td>
<td>51, aSAH</td>
<td>H&amp;H: 1–4, median 2–3</td>
<td>Acute phase: 5–10 days Chronic phase: 3–6 months</td>
<td>Acute phase: any degree 37, GH 12, LH/FSH 30, ACTH 8, TSH 6 Chronic phase: any degree 27, GH 20, LH/FSH 4, ACTH 18, TSH 2</td>
<td>PD patients: Acute phase: lower median GOS at discharge, ( P = 0.018 ). Chronic phase: lower median GOS at follow-up, ( P = 0.041 )</td>
</tr>
</tbody>
</table>

(Continued)
In conclusion, limited data are available on the prevalence of PD in stroke. PD has been better studied in TBI and aSAH populations and seems to be a prevalent condition. However, the exact prevalence is still subject to controversy, partly due to methodological differences between studies, including the diagnostic methods used to define endocrinological dysfunction, the focus on the acute phase, chronic phase or both and the presence and duration of a follow-up. Most studies showed a higher prevalence of PD in the acute phase than in the chronic phase. Therefore, it is questionable whether this neuroendocrine dysfunction based on pathological laboratory values can be attributed to a physiological adaptation to critical illness. For example, hypogonadism is relevant to prevent reproduction during illness. Thus, it may be a physiological response in a situation where all resources are necessary for regeneration processes. However, new-onset PD in the chronic phase was also found. PD might be linked to worse quality of life and outcome; however, this relationship and thus the clinical relevance needs further study. Since the exact mechanism of PD after acute acquired brain injury is not exactly known, it is not clear whether the results of studies on aSAH and TBI can be extrapolated to the stroke population. Suggested mechanisms of PD are mechanical forces, hypotension, hypoxia and raised intracranial pressure (4, 5). Possible predictors of PD in aSAH and aSAH patients screened within 2 weeks after admittance to neurorehabilitation, 28.5% showed lowered values in at least one hormone of the hypothalamus–pituitary axis (36). The most common finding was a decrease of testosterone. Stimulation tests performed in patients with abnormalities in the screening or in patients with clinical signs of PD revealed GHD in 20.7% (19/92) and hypocortisolism in 23.7% (28/118). However, most patients were clinically not diagnosed as pituitary insufficient and none of the patients with GHD or hypocortisolism received substitution therapy. In a post hoc analysis, 13 patients with low testosterone levels were given hormone replacement therapy. After 4 weeks of treatment, 4 out of these 13 showed an increase in hemoglobin level of >2 g/dL and 5 out of 13 showed an improvement of the Barthel Index of >20 points, possibly indicating a benefit from the hormone replacement therapy. Randomized placebo controlled trials are highly needed to further investigate the effect of hormonal suppletion in patients with PD after acute acquired brain injury.

In conclusion, limited data are available on the prevalence of PD in stroke. PD has been better studied in TBI and aSAH populations and seems to be a prevalent condition. However, the exact prevalence is still subject to controversy, partly due to methodological differences between studies, including the diagnostic methods used to define endocrinological dysfunction, the focus on the acute phase, chronic phase or both and the presence and duration of a follow-up. Most studies showed a higher prevalence of PD in the acute phase than in the chronic phase. Therefore, it is questionable whether this neuroendocrine dysfunction based on pathological laboratory values can be attributed to a physiological adaptation to critical illness. For example, hypogonadism is relevant to prevent reproduction during illness. Thus, it may be a physiological response in a situation where all resources are necessary for regeneration processes. However, new-onset PD in the chronic phase was also found. PD might be linked to worse quality of life and outcome; however, this relationship and thus the clinical relevance needs further study. Since the exact mechanism of PD after acute acquired brain injury is not exactly known, it is not clear whether the results of studies on aSAH and TBI can be extrapolated to the stroke population. Suggested mechanisms of PD are mechanical forces, hypotension, hypoxia and raised intracranial pressure (4, 5). Possible predictors of PD in aSAH and aSAH patients screened within 2 weeks after admittance to neurorehabilitation, 28.5% showed lowered values in at least one hormone of the hypothalamus–pituitary axis (36). The most common finding was a decrease of testosterone. Stimulation tests performed in patients with abnormalities in the screening or in patients with clinical signs of PD revealed GHD in 20.7% (19/92) and hypocortisolism in 23.7% (28/118). However, most patients were clinically not diagnosed as pituitary insufficient and none of the patients with GHD or hypocortisolism received substitution therapy. In a post hoc analysis, 13 patients with low testosterone levels were given hormone replacement therapy. After 4 weeks of treatment, 4 out of these 13 showed an increase in hemoglobin level of >2 g/dL and 5 out of 13 showed an improvement of the Barthel Index of >20 points, possibly indicating a benefit from the hormone replacement therapy. Randomized placebo controlled trials are highly needed to further investigate the effect of hormonal suppletion in patients with PD after acute acquired brain injury.

Table 3  Continued.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%)</th>
<th>Association of PD with functional outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimopoulou, 2004 (23)</td>
<td>Cross-sectional</td>
<td>30, aSAH</td>
<td>H&amp;H 1–5, median 2</td>
<td>12–24 months</td>
<td>Any degree 47, GH 37, LH/FSH 13, ACTH 10, TSH 7</td>
<td>No association with functional outcome measured with mRS and Barthel Index</td>
</tr>
<tr>
<td>Kreitschmann-Andermahr, 2004 (24)</td>
<td>Cross-sectional</td>
<td>40, aSAH</td>
<td>55% H&amp;H 1–2, 45% H&amp;H 3–4</td>
<td>12–72 months</td>
<td>Any degree 55, GH 20.0, LH/FSH NR, ACTH 40.0, TSH 2.5</td>
<td>No association with functional outcome measured with GOS</td>
</tr>
<tr>
<td>Pereira, 2013 (25)</td>
<td>Cross-sectional</td>
<td>66, aSAH</td>
<td>71.2% H&amp;H 1–2, 25.8% H&amp;H 3–4, 3% H&amp;H 5</td>
<td>0–15 days, mean 7.4</td>
<td>Any degree 59.1, GH 28.7, LH/FSH 34.8, ACTH 18.1, TSH 9</td>
<td>No association with functional outcome at hospital discharge measured with GOS</td>
</tr>
<tr>
<td>Srinivasan, 2009 (26)</td>
<td>Cross-sectional</td>
<td>34: 18 TBI, 16 aSAH</td>
<td>100% GCS ≤12</td>
<td>5–12 months</td>
<td>Any degree 58.8, GH 17.6, LH/FSH 0, ACTH 50, TSH 20.6</td>
<td>PD patients: lower functional independence score, P=0.027</td>
</tr>
</tbody>
</table>

ACTH, adrenocorticotropic hormone; aSAH, aneurysmatic subarachnoid hemorrhage; BDI-II, Beck Depression Inventory-II; BMI, body mass index; DRS, Disability Rating Scale; FSH, follicle-stimulating hormone; GCS, Glasgow Coma Scale score; GH, growth hormone; GHD, growth hormone deficiency; GOS, Glasgow Outcome Scale; HDL, high-density lipoprotein; H&H, Hunt and Hess score; ILS, Independent Living Scale; LDL, low-density lipoprotein; LH, luteinizing hormone; mRS, modified Ranking Scale; NR, not reported; PHH, persistent hypogonadotropic hypogonadism; PD, pituitary dysfunction; TBI, traumatic brain injury; TSH, thyroid-stimulating hormone.

http://www.endocrineconnections.org
https://doi.org/10.1530/EC-18-0147
© 2018 The authors
Published by Bioscientifica Ltd

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Downloaded from Bioscientifica.com at 12/12/2018 11:37:35AM via free access
Table 4  Predictors of pituitary dysfunction in traumatic brain injury and aneurysmatic subarachnoid hemorrhage.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%)</th>
<th>Predictors of PD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goto, 2016 (28)</td>
<td>Cross-sectional</td>
<td>59, aSAH</td>
<td>56% H&amp;H 1–2, 33.9% H&amp;H 3–4, 10.1% H&amp;H 5</td>
<td>3-36 months</td>
<td>Any degree NR, GH 8.5, LH/FSH 0, ACTH 0, TSH 0</td>
<td>Aneurysms in all GHD patients in internal carotid artery or anterior cerebral artery increased age (mean difference 3.19; 95% CI 0.31–6.08; 19 studies, n = 1057) Traumatic brain injury severity (risk ratio 2.15; 95% CI 1.20–3.86; 7 studies, n = 425) Skull fractures (risk ratio 1.73; 95% CI 1.03–2.91; 6 studies, n = 357)</td>
</tr>
<tr>
<td>Lauzier, 2014 (29)</td>
<td>Systematic review, 27 studies</td>
<td>See predictors</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Increased age (mean difference 3.19; 95% CI 0.31–6.08; 19 studies, n = 1057) Traumatic brain injury severity (risk ratio 2.15; 95% CI 1.20–3.86; 7 studies, n = 425) Skull fractures (risk ratio 1.73; 95% CI 1.03–2.91; 6 studies, n = 357)</td>
</tr>
<tr>
<td>Klose, 2007 (30)</td>
<td>Cross-sectional</td>
<td>104, TBI</td>
<td>42.3% GCS 13–15, 19.2% GCS 9–12, 38.5% GCS ≤ 8</td>
<td>10-27 months, mean 13</td>
<td>Any degree 15, GH 15, LH/FSH 2, ACTH 5, TSH 2</td>
<td>Severe TBI, OR 10.1, 95% CI 2.1–48.4 Increased intracranial pressure, OR 6.5, 95% CI 1.0–42.2 Longer duration of intubation, OR 7.7, 95% CI 1.9–31.7</td>
</tr>
<tr>
<td>Schneider, 2008 (31)</td>
<td>Prospective cohort</td>
<td>78, TBI</td>
<td>NR</td>
<td>3 and 12 months</td>
<td>3 months: any degree 56 12 months: any degree 36</td>
<td>Diffuse axonal injury at 3 or 12 months, P = 0.039 Basal skull fracture at 3 and 12 months, P = 0.029 and 0.012, resp. Higher age at 12 months: OR 11.494 (no CI or P reported)</td>
</tr>
<tr>
<td>Khajeh, 2015 (32)</td>
<td>Prospective cohort</td>
<td>84, aSAH</td>
<td>79% GCS 13–15, 13% GCS 9–12, 8% GCS ≤ 8</td>
<td>At baseline, 6 months and 14 months</td>
<td>Baseline: any degree 44, GH 31, LH/FSH 34, ACTH 1 TSH 1 6 months: any degree 26, GH 10, LH/FSH 20, ACTH NR, TSH NR 14 months: any degree 7, GH 6, LH/FSH 5, ACTH NR, TSH NR</td>
<td>Hydrocephalus as independent predictor of PD 6 months after aSAH (OR 3.3 CI 2.7–3.8)</td>
</tr>
</tbody>
</table>

(Continued)
TBI patients were aneurysm location in anterior cerebral artery of internal carotid artery, severity of injury, skull fractures, hydrocephalus, raised intracranial pressure and diffuse axonal injury. Since younger as well as higher age were associated with PD in different studies, the role of this factor in developing PD is uncertain. Although not all of the possible predictors are present in stroke, some might be applicable in this condition as well.

### Poststroke fatigue

Fatigue is a nonspecific complaint reported in the general population as well as in specific patient groups seen in primary care settings. Overall, 23–59.5% of patients with stroke (predominantly ischemic) rated fatigue as the worst or one of the worst poststroke symptoms (37, 38, 39). The multidimensional and subjective nature of fatigue makes it a difficult subject to study. Normal fatigue is defined as a state of general tiredness, which is the result of overextension and can be ameliorated by rest (40). It is acute, with a rapid onset and shorter duration. Pathological fatigue on the other hand is perceived to be abnormal or excessive and does not respond well to rest. It has been proposed that PSF in the ‘early phase’ might be a different construct than late phase PSF, with early fatigue being associated with biological factors and late fatigue being more attributable to psychological and behavioral factors (41). PSF has also been defined as a combination of subjective fatigue (a feeling of early exhaustion, weariness and aversion to effort) and objective fatigue (observable and measurable decrement in performance occurring with the repetition of a physical or mental task) (42). PSF in the acute phase has been linked to a lower independence in activities of daily living in the chronic phase, also after transient ischemic attack (43, 44).

Prevalence rates of PSF vary among studies, depending on methodological differences such as type of fatigue scales and cutoff points used. In a systematic review of longitudinal studies including nine studies, the prevalence of fatigue after hemorrhagic or ischemic stroke varied between 35% and 92% from admission to 36 months (45). In seven studies, the prevalence declined over time (n = 764) while in two studies, it increased (n = 195). In a population-based study, the PSF prevalence after 6 months in patients with minor stroke (ischemic or hemorrhagic,
Table 5 Pituitary dysfunction in traumatic brain injury and aneurysmatic subarachnoid hemorrhage and association with fatigue.

<table>
<thead>
<tr>
<th>First author, year</th>
<th>Design</th>
<th>N</th>
<th>Severity on admission</th>
<th>Time after event</th>
<th>Prevalence of PD and axes involved (%)</th>
<th>Association with fatigue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kreitschmann-Andermahr, 2007 (57)</td>
<td>Cross-sectional</td>
<td>40, aSAH</td>
<td>55% H&amp;H 1–2, 45% H&amp;H 3–4</td>
<td>Mean 27.3 ± 15 months, range 12–66</td>
<td>Any degree NR, GH 20, LH/FSH NR, ACTH 40, TSH 2.5</td>
<td>Correlation between basal cortisol level and energy (NHP, r = –0.44, P &lt; 0.01)</td>
</tr>
<tr>
<td>Khajeh, 2016 (58)</td>
<td>Prospective cohort</td>
<td>84, aSAH</td>
<td>78.6% GCS 13–15, 13.1% GCS 9–12, 8.3% GCS ≤8</td>
<td>At discharge, 6 months and 14 months</td>
<td>Discharge: any degree 30, GH 11, LH/FSH NR, TSH NR 6 months: any degree 28, GH 12, LH/FSH NR, TSH NR 12 months: any degree 33, GH 15, LH/FSH NR, TSH NR</td>
<td>No effect of PD or GHD on fatigue over time (FSS, P = 0.8 and 0.23, resp.)</td>
</tr>
<tr>
<td>Klose, 2015 (60)</td>
<td>Cross-sectional</td>
<td>439, TBI</td>
<td>71% GCS 13–15, 10% GCS 9–12, 19% GCS ≤8</td>
<td>Median 2.5 years, range 1.1–4.0</td>
<td>Any degree 20, GH 6.6, LH/FSH 5.4, ACTH 4.0, TSH 0.5</td>
<td>Increased physical fatigue in PD patients (MFI-20, P = 0.03). No longer significant after adjustment for gender, age and waist circumference</td>
</tr>
<tr>
<td>Bavisetty, 2008 (61)</td>
<td>Prospective cohort</td>
<td>70, TBI</td>
<td>Median GCS 7, range 3–15</td>
<td>3 months and 6–9 months</td>
<td>3 months: any major deficit 5, GH 16, LH/FSH 18, ACTH 3, TSH 0 6–9 months: any major deficit 21, GH 16, LH/FSH 10.5, ACTH 0, TSH 0</td>
<td>Lower scores on energy and fatigue in GHD/GHI patients at 6–9 months (SF-36, 48.3 ± 21.9 vs 64.2 ± 24.0, univariate P = 0.053, multivariate P = 0.03) No difference in energy and fatigue between patients with and without major hormonal deficiencies at 6–9 months (SF-36 and neurobehavioral rating scale)</td>
</tr>
<tr>
<td>Kelly, 2006 (62)</td>
<td>Prospective cohort</td>
<td>44, TBI</td>
<td>GCS 3–14, median 7</td>
<td>6–9 months</td>
<td>GHD and GHI 18</td>
<td>Reduced scores on energy and fatigue in GHD/GHI patients (SF-36, 47.7 ± 22.5 vs 63.7 ± 24.3, P = 0.05) No difference in fatigue on neurobehavioral rating scale fatigue between GHD/GHI and GH-sufficient patients, P = 0.50</td>
</tr>
<tr>
<td>Englander, 2010 (63)</td>
<td>Cross-sectional</td>
<td>119, TBI</td>
<td>Relatively even distribution of mild, moderate and severe TBI</td>
<td>9 ± 7.6 years</td>
<td>GH 65, LH/FSH 15 in men (low testosterone), low morning cortisol 64, TSH 12</td>
<td>No correlation between any measure of abnormal endocrine function and fatigue</td>
</tr>
</tbody>
</table>

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
PD and fatigue after acute acquired brain injury

There is some evidence that PD might play a role in fatigue after other acute acquired brain injury, although the findings are inconsistent (Table 5). In a cross-sectional study of 40 aSAH survivors at least 1 year after the hemorrhage, the relation between disturbances in hypothalamic-pituitary–adrenal and somatotropic axes and quality of life and psychiatric sequelae were investigated (60). A significant correlation was shown between lower basal cortisol level and the Nottingham Health Profile (NHP) subscale energy. In a stepwise multiple regression analysis, severe GHD was the first predictor for the NHP subscale energy. However, a prospective cohort study with 84 aSAH survivors with a follow-up of 14 months found no association between PD or GHD and fatigue (61). Another cross-sectional study investigated pituitary function in relation to cerebral blood flow in ten patients with post-SAH fatigue approximately 1 year after the hemorrhage.
(62). Disturbances in gonadotropin function and/or GH release were detected in three patients, and in two patients only relatively weak indications of PD were detected. In these five individuals, there was a corresponding area of decreased cerebral blood flow, crossing the midline in the hypothalamic and subfrontal region. These results suggest a possible relationship between pathologic cerebral blood flow and PD. However, the association between PD and post-SAH fatigue seems weak, since five patients were fatigued but had normal pituitary function. Furthermore, there was no control group of non-fatigued SAH patients. In a Danish cross-sectional study, 439 patients with a history of head trauma underwent assessment of anterior pituitary function and outcome variables including fatigue 2.5 years after TBI (63). Patients with PD had increased physical fatigue relative to patients with intact pituitary function. However, after adjustment for age, sex and waist circumference, the relation did not remain significant. In a prospective cohort study of 70 patients after TBI, 11 patients were identified with GHD or GH-insufficiency, and these patients had worse quality-of-life scores on the Short Form-36 domains of energy and fatigue compared to GH-sufficient patients (64). However, there was no significant difference on this scale in patients with major hormonal deficiencies vs no major hormonal deficiencies and on the neurobehavioral rating scale fatigue between patients with and without any pituitary deficiency. Similar results were found in a prospective study 6–9 months post injury (65). Other studies did not find any correlation between PD and fatigue after TBI (66, 67, 68). A cross-sectional study of 64 patients 10±8 years after TBI found higher GH levels to be significantly associated with higher scores on fatigue, contradicting the hypothesis that post-acute TBI fatigue is associated with GHD (69). There was a trend between lower basal cortisol and higher scores on fatigue scales, which is in line with previous studies on fatigue after aSAH.

Effect of hormonal suppletion on fatigue

To our knowledge, only one open-label study evaluated the effect of GH suppletion on fatigue in 15 patients 1–5 years post TBI with abnormal GH secretion, with a treatment duration of 1 year (70). Peak O₂ consumption, peak oxygen pulse and peak ventilation all significantly increased (P<0.05). The perceptual rating of exercise-induced fatigability was reduced by 25%, although this result was not significant (P=0.06). However, fatigue as measured with the Fatigue Severity Scale significantly declined over time (P=0.039). These results suggest that GH substitution has a positive impact on cardiorespiratory fitness and a positive impact on perceptual fatigue in TBI survivors with altered GH secretion. Important limitations of this study are the lack of a control group and of blinding for treatment allocation.

To conclude, data on the relation of PD and fatigue after acute acquired brain injury is scarce and inconsistent and only a few studies had fatigue as primary endpoint. Given the high prevalence of PD, it seems reasonable to screen for hypopituitarism after acute neurologic injury and annually thereafter, although the contribution to fatigue remains unclear.

Conclusion

PSF is a common and debilitating condition and much is still unknown about its etiology. The symptomatology of PSF overlaps with that of PD, a condition whose co-prevalence in stroke as well as in other causes of acute acquired brain injuries has gathered an increased amount of attention over the past years. However, the exact prevalence of PD in these conditions is still subject to controversy, partly due to methodological differences between studies. Thereby, limited data exist on the association between PD and clinical outcome including fatigue. More studies are needed to establish the clinical relevance of PD, and to our particular interest, the effect on fatigue after ischemic stroke. If a relevant association between PD and PSF exists, double-blinded studies should be performed to study the effect of substituting the deficient pituitary hormones as a novel treatment option to improve outcome.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


Pituitary dysfunction and stroke


Critical Care Medicine 2014 42 712–721. (https://doi.org/10.1097/CCM.0000000000000046)
43 Lerdal A & Gay CL. Fatigue in the acute phase after first stroke predicts poorer physical health 18 months later. Neurology 2013 81 1581–1587. (https://doi.org/10.1212/wnl.0b013e3182a94771)


